Shares of Prothena Corporation plc (PRTA) soared on Wednesday after Danish drugmaker Novo Nordisk (NVO) said that it expects ...

Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings call on August 6, 2025 that they expect to advance coramitug, a potential ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

On August 6, 2025, Prothena announced that its partner Novo Nordisk will advance coramitug, a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with ...

Shares of Prothena climbed after Novo Nordisk said during its second-quarter earnings call that it expects to advance a treatment for amyloidosis it bought from Prothena in 2021. The Dublin company's ...

In the assessment of 12-month price targets, analysts unveil insights for Prothena Corp, presenting an average target of $34.67, a high estimate of $81.00, and a low estimate of $4.00. Observing a ...

Prothena (PRTA) delivered earnings and revenue surprises of -67.57% and -79.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Return on Equity (ROE): Prothena Corp's ROE falls below industry averages, indicating challenges in efficiently using equity ...

DUBLIN (AP) — DUBLIN (AP) — Prothena Corp. (PRTA) on Monday reported a loss of $125.8 million in its second quarter. The Dublin-based company said it had a loss of $2.34 per share. Losses, adjusted ...

Prothena's therapeutics for Parkinson's (Ph 2) and Alzheimer's (Ph 1) are differentiated and best-in-class antibodies. Roche and Bristol Myers have collaborations with Prothena for the Parkinson's ...

Prothena is a biotech with a unique, epitope targeting approach to drug development. It could earn billions in milestone payments over the next few years, and may become profitable in FY21.

Thanks to this collaboration, Prothena could potentially end up with a total of $2.2 billion, including all funds put forth by Bristol Myers Squibb for U.S. and global rights and regulatory and ...